[1] Legosz P, Otworowski M, Sibilska A, et al. Heterotopic ossification: a challenging complication of total hip arthroplasty: risk factors, diagnosis, prophylaxis, and treatment[J]. Biomed Res Int, 2019, 2019:1-8.
[2] Foley K L, Hebela N, Keenan M A, et al. Histopathology of periarticular non-hereditary heterotopic ossification[J]. Bone, 2018, 109: 65-70.
[3] Kan C, Ding N, Yang J, et al. BMP-dependent, injury-induced stem cell niche as a mechanism of heterotopic ossification[J]. Stem Cell Res Ther, 2019, 10(1): 1-17.
[4] Lounev V Y, Ramachandran R,Wosczyna M N, et al. Identification of progenitor cells that contribute to heterotopic skeletogenesis[J]. 2009, 91(3):652-663.
[5] Medici D, Olsen B R. The role of endothelial-mesenchymal transition in heterotopic ossification[J]. J Bone Miner Res, 2012, 27(8): 1619-1622.
[6] Ambrosi T H, Longaker M T, Chan C K. A revised perspective of skeletal stem cell biology[J]. Front Cell Dev Biol, 2019, 7(189):1-20.
[7] Gugala Z, Olmsted E A, Xiong Y, et al. Trauma-induced heterotopic ossification regulates the blood-nerve barrier[J]. Front Neurol, 2018, 9(408):1-8.
[8] Bishop G B, Einhorn T A. Current and future clinical applications of bone morphogenetic proteins in orthopaedic trauma surgery[J]. Int Orthop, 2007, 31(6): 721-727.
[9] Yoshida Y, Tanaka S, Umemori H, et al. Negative regulation of BMP/Smad signaling by Tob in osteoblasts[J]. Cell, 2000, 103(7): 1085-1097.
[10] Covello K L, Simon M C. HIFs, hypoxia, and vascular development[J]. Curr Top Dev Biol, 2004, 62: 37-54.
[11] Huang Y, Wang X, Lin H. The hypoxic microenvironment: a driving force for heterotopic ossification progression[J]. Cell Commun Signal, 2020, 18(1): 1-10.
[12] Licini C, Farinelli L, Cerqueni G, et al. Heterotopic ossification in a patient with diffuse idiopathic skeletal hyperostosis: Input from histological findings[J]. Eur J Histochem, 2020, 64(4):317-322
[13] Lespasio M J, Guarino A J. Awareness of heterotopic ossification in total joint arthroplasty: a primer[J]. Perm J, 2020, 24(19):211-212.
[14] 李文革, 田 军, 孙 博, 等.异位骨化的影像学表现(附7例分析)[J]. 医学影像学杂志, 2014, 24(7): 1217-1219.
[15] 鞠金勇, 喻 都, 王永建, 等.异位骨化影像学早期诊断研究进展[J]. 国际骨科学杂志, 2016, 37(5): 282-285.
[16] 牟薪砚, 常晓丹, 赵德伟, 等.全髋关节置换后异位骨化的成因及影像诊断[J]. 中国组织工程研究, 2019, 0(16):2538-2544.
[17] Wang Q, Zhang P, Li P, et al. Ultrasonography monitoring of trauma-induced heterotopic ossification: guidance for rehabilitation procedures[J]. Front Neurol, 2018, 9(771):1-9.
[18] 贺倩倩, 陈筱雪, 杨少玲, 等.彩色多普勒超声显示早期创伤后异位骨化的实验研究[J]. 中华超声影像学杂志, 2020, 29(2):175-179,
[19] 赵 航, 肖海军. 骨硬化蛋白和骨形成蛋白-4在诊断异位骨化中的临床意义[J]. 河北医药, 2019, 41(3):396-399,
[20] Rivera J C, Hsu J R, Noel S P, et al. Locally delivered nonsteroidal antiinflammatory drug: a potential option for heterotopic ossification prevention[J]. Clin Transl Sci, 2015, 8(5): 591-593.
[21] Zhu X T, Chen L, Lin J H. Selective COX-2 inhibitor versus non-selective COX-2 inhibitor for the prevention of heterotopic ossification after total hip arthroplasty: A meta-analysis[J]. Medicine (Baltimore), 2018, 97(31): e11649-11658.
[22] Migliorini F, Trivellas A, Eschweiler J, et al. NSAIDs for prophylaxis for heterotopic ossification after total hip arthroplasty: a Bayesian network meta-analysis[J]. Calcif Tissue Int, 2021; 108(2): 196-206.
[23] 张 超,吕 欣. 髋臼骨折固定后的异位骨化:危险因素、预防及其治疗进展[J]. 中国组织工程研究, 2021, 25(9):1434-1439.
[24] Dow T, King J P, Wong I H. The reduction of heterotopic ossification incidence after hip arthroscopy in patients treated with selective cyclooxygenase 2 inhibitor (celecoxib)[J]. Arthroscopy, 2020, 36(2): 453-461.
[25] Beckmann J T, Wylie J D, Kapron A L, et al. The effect of NSAID prophylaxis and operative variables on heterotopic ossification after hip arthroscopy[J]. Am J Sports Med, 2014, 42(6): 1359-1364.
[26] Beckmann J T, Wylie J D, Potter M Q, et al. Effect of naproxen prophylaxis on heterotopic ossification following hip arthroscopy: a double-blind randomized placebo-controlled trial[J]. J Bone Joint Surg Am, 2015, 97(24): 2032-2037.
[27] 吴大鹏, 徐海斌, 李小伟, 等. 双氯芬酸钠缓释片预防髋臼骨折术后异位骨化的临床研究[J]. 重庆医学, 2011, 40(12):1221-1222.
[28] Lin H, Shi F, Jiang S, et al. Metformin attenuates trauma-induced heterotopic ossification via inhibition of bone morphogenetic protein signalling[J]. J Cell Mol Med, 2020, 97(31):1-10.
[29] Cai L, Wang Z, Luo X, et al. Optimal strategies for the prevention of heterotopic ossification after total hip arthroplasty: a network meta-analysis[J]. Int J Surg, 2019, 62: 74-85.
[30] Morcos M, Smith K, Tanzer M. The effect of late radiotherapy on the progression of heterotopic ossification following total hip arthroplasty[J]. Eur J Orthop Surg Traumatol, 2018, 28(6): 1125-1131.
[31] Tao MJ, Probyn L, Drost L, et al. Efficacy of prophylactic radiotherapy in the treatment of heterotopic ossification[J]. Clin Oncol (R Coll Radiol), 2018, 30(6): 393-395.
[32] Hu Z H, Chen W, Sun J N, et al. Radiotherapy for the prophylaxis of heterotopic ossification after total hip arthroplasty: a systematic review and meta-analysis of randomized controlled trails[J]. Med Dosim, 2020, 46(1):65-73.
[33] Legosz P, Drela K, Pulik L, et al. Challenges of heterotopic ossification-molecular background and current treatment strategies[J]. Clin Exp Pharmacol Physiol, 2018, 45(12): 1229-1235.
[34] Strong A L, Spreadborough P J, Dey D, et al. BMP ligand trap ALK3-Fc attenuates osteogenesis and heterotopic ossification in blast-related lower extremity trauma[J]. Stem Cells Dev, 2021, 30(2): 91-105.
[35] Shimono K, Tung W E, Macolino C, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists[J]. Nat Med, 2011, 17(4): 454-460.
[36] Mao D, Pan X, Rui Y, et al. Matrine attenuates heterotopic ossification by suppressing TGF-beta induced mesenchymal stromal cell migration and osteogenic differentiation[J]. Biomed Pharmacother, 2020, 127: 1-7.
[37] Tu B, Liu S, Yu B, et al. miR-203 inhibits the traumatic heterotopic ossification by targeting Runx2[J]. Cell Death Dis, 2016, 7(10): 2436-2446.
[38] Mishra S, Vaughn A D, Devore D I, et al. Delivery of siRNA silencing Runx2 using a multifunctional polymer-lipid nanoparticle inhibits osteogenesis in a cell culture model of heterotopic ossification[J]. Integr Biol (Camb), 2012, 4(12): 1498-1507.
[39] Juarez J K, Wenke J C, Rivera J C. Treatments and preventative measures for trauma induced heterotopic ossification: a review[J]. Clin Transl Sci, 2018, 11(4): 365-370.
[40] He S K, Yi M, Zhong G, et al. Appropriate excision time of heterotopic ossification in elbow caused by trauma[J]. Acta Orthop Traumatol Turc, 2018, 52(1): 27-31.
[41] Kitayama K, Kawakami Y, Fukui T, et al. Rescue of ankylosing hip following open reduction and internal fixation of acetabular fracture by surgical resection of heterotopic ossification: a case report[J]. Int J Surg Case Rep, 2018, 53: 107-111.
[42] Cole P A, Dugarte A J, Talbot M, et al. Early resection of ectopic bone in patients with heterotopic ossification about the hip after trauma[J]. Injury, 2020, 51(3): 705-710.
[43] Kitterman J A, Kantanie S, Rocke D M, et al. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva[J]. Pediatrics, 2005, 116(5): e654-e661.
[44] 张惠法, 蔡文辉, 许建安,等.活血止痛汤预防全髋置换术后异位骨化的临床观察[J]. 中国中医骨伤科杂志, 2000, 8(2): 29-30.
[45] 杨文雪, 朱笑夏, 陶庆文,等.补肾舒脊颗粒对强直性脊柱炎异位骨化相关因子的影响[J]. 中华中医药杂志, 2019, 34(9): 4405-4409.
[46] 刘兴华, 蒋协远, 公茂琪, 等. 放射治疗加口服吲哚美辛预防肘关节异位骨化切除术后的复发[J]. 北京大学学报:医学版, 2016, 48(2):230-233.